Last year was a dud for the big health insurer. Could 2016 be dazzling?
Jardiance significantly reduced cardiovascular disease deaths in trials, but the industry is slow to embrace it.
With earnings rapidly incoming, here's what you need to watch for when Anthem reports on Jan. 27.
With its largest customer threatening to leave, the country's biggest PBM could be in for a rotten year.
Maybe. But more importantly, what will 2016 mean for 2017 and 2018?
Despite a tumbling tape, shares in these three healthcare companies rallied.
These three growth stocks are cheap now, but they may not stay cheap for much longer.
Even as the GOP votes to repeal Obamacare for the 62nd time, these three stocks look primed for further gains.
Or perhaps a better title would be "least worst."
It was an ugly week for the market and healthcare ETFs were hit hard, yet this one ETF once again proved itself to be the top performer of the bunch.